Over 50% of U.S. Adults Are Eligible for Ozempic and Wegovy, But Access Remains Difficult
By Stephanie Brown for Verywellhealth, December 13, 2024
Semaglutide has been approved by the Food and Drug Administration (FDA) for type 2 diabetes management, weight loss, and heart disease prevention. About 137 million Americans—more than half of all adults—are eligible for this drug based on these treatment indications, according to a recent JAMA Cardiology research letter.
“Some people may not be ‘eligible’ but have access and are using it off-label. Many others have the indications yet do not have access—whether it’s because it’s not affordable or insurance doesn’t cover it or it isn’t being prescribed,” Dima Mazen Qato, PharmD, MPH, PhD, an associate professor of clinical pharmacy and spatial sciences at the University of Southern California, told Verywell in an email.
Read more here